Glycogen synthase kinase-3 in the etiology and treatment of mood disorders. - Test2 - elhamkhani - TriplyDB

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

http://www.wikidata.org/entity/Q30474415

about

Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder Potential Roles of Adropin in Central Nervous System: Review of Current Literature Regulation of inflammation and T cells by glycogen synthase kinase-3: links to mood disorders Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice Unique Effects of Acute Aripiprazole Treatment on the Dopamine D2 Receptor Downstream cAMP-PKA and Akt-GSK3β Signalling Pathways in Rats Ethyl Pyruvate Combats Human Leukemia Cells but Spares Normal Blood Cells Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action.Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase.Gene expression analysis of novel genes in the prefrontal cortex of major depressive disorder subjects.Multiple levels of impaired neural plasticity and cellular resilience in bipolar disorder: developing treatments using an integrated translational approach Fluoxetine prevents development of an early stress-related molecular signature in the rat infralimbic medial prefrontal cortex. Implications for depression?Inflammation and lithium: clues to mechanisms contributing to suicide-linked traits.Impairments in cognition and neural precursor cell proliferation in mice expressing constitutively active glycogen synthase kinase-3.Association between obesity and depression in patients with diabetes mellitus type 2; a study protocol.A pivotal role of GSK-3 in synaptic plasticity.Teaching evolution to psychiatrists in Venezuela: comparison with medical students and other medical specialists: a pilot study Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial.Disruption of circadian rhythmicity and suprachiasmatic action potential frequency in a mouse model with constitutive activation of glycogen synthase kinase 3.Glycogen synthase kinase-3 levels and phosphorylation undergo large fluctuations in mouse brain during development.Altered concentrations of amyloid precursor protein metabolites in the cerebrospinal fluid of patients with bipolar disorder GSK3β isoform-selective regulation of depression, memory and hippocampal cell proliferation.Stress-induced neuroinflammation is mediated by GSK3-dependent TLR4 signaling that promotes susceptibility to depression-like behavior.A role for WNT/β-catenin signaling in the neural mechanisms of behavior.The ups and downs of bipolar disorder research.GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of ketamine Characterization of maleimide-based glycogen synthase kinase-3 (GSK-3) inhibitors as stimulators of steroidogenesis.Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome.Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.Modulation of Synaptic Plasticity in the Cortex Needs to Understand All the Players.DISC1 Pathway in Brain Development: Exploring Therapeutic Targets for Major Psychiatric Disorders.Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments.GSK-3β, a pivotal kinase in Alzheimer disease.Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases Kinase targets in CNS drug discovery.FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications.Stressed and Inflamed, Can GSK3 Be Blamed?Wnt and GSK3 Signaling Pathways in Bipolar Disorder: Clinical and Therapeutic Implications Mood Stabilizers and the Influence on Global Leukocyte DNA Methylation in Bipolar Disorder.Glycogen synthase kinase-3β in patients with bipolar I disorder: results from a prospective study.The Nav1.2 channel is regulated by GSK3.

P2860

Q24626017-2D67A4E0-A49F-4994-A4F6-B5EBFAA3246E Q26742073-8C12AC98-FCBA-411D-9CAF-F5A6A7074967 Q27027115-6A920D4D-B1E4-4C2F-A2F6-E74ABC7D5495 Q28485938-1A149D56-0577-4DC8-A163-DC319D570546 Q28546441-A46AFFFB-DC41-4B24-A342-173D3C03DBBA Q28553790-668F5185-40BE-46A2-9A7D-4CE0D441452F Q30453635-41C46443-1E66-42FD-8D11-F9BDC85AB2BC Q30465622-FD1C2581-106F-4C63-AA4A-5836B6B5ACBD Q33874356-B6A593CD-D9AA-4DA7-8DDA-5AA0022B984D Q34268501-A49ED68A-86D7-4A53-9223-7B0B94DFE065 Q34449524-9325AC4C-49D8-401D-8A23-7FD05163A62A Q34731214-1E904E39-8474-4E55-A8F1-E607E4DB12A0 Q35146005-4F89C4C5-BDDB-4ED8-B551-ECF7C5607D2D Q35173316-9501ED03-A4F8-42A8-A4E3-6AF07434DAD3 Q35757839-D3B39AE6-4E2A-473E-A365-C932774F551D Q36040085-C4A7FC95-C8ED-479A-BD0E-2FA30A18EE60 Q36100305-FC4A9602-3A99-4F92-88B4-6FD211DFBCE4 Q36374243-4C144D69-1536-4AE9-AC9B-90E7880A8DEB Q36419565-941A4D41-13BC-43D1-9E27-D1CE8430A999 Q36610063-BC22E38F-9083-4191-8602-BAEC0464B22E Q36649760-730EF1E4-44B8-4F07-A716-12ED89FA27C0 Q36665088-689363DF-37C4-4D9E-9B2F-EA2F700E845A Q37109722-E589365E-1A04-4CEA-9224-6CD2546F9444 Q37134759-5B260DE2-0B50-457C-8400-1656AAAEB343 Q37172762-BE28EBF3-A073-4B10-96CE-706BDA97BCB9 Q37184659-2A19B921-5394-46C7-9A02-42A3BBCCDE11 Q37416780-3B94760D-E648-4B42-9FF4-01CA6BB8C02D Q37417156-669EACE1-3411-4AC9-942F-E066FC6A8E3D Q37617476-CE8A239B-12FB-44BD-BF95-ADC73B1DD128 Q37998459-784EA401-E13E-4C0C-97F7-F012DED37932 Q38126701-2341949F-F662-4BFA-8E24-FE5B517B4362 Q38218085-7ED2BD4A-203B-481B-AA01-C4DD2F1D1486 Q38272835-EB170942-9CA1-4B4B-840D-E3BB49D0D169 Q38760031-68E0C476-395C-495C-9438-32F63DCDEEFB Q38890067-B7D690FC-24FF-47A5-A3B5-FC7CA3C941F6 Q39017112-7E7E2ABA-7F6F-495D-A3D4-08AB57DEFC89 Q39267337-BAC16B76-780B-4EEE-BA39-B750D1AA5C1C Q39415079-89FA1345-3A07-4020-9693-63554AF2ABDC Q39668647-88DDE0C1-DF82-4B93-B564-F3F526D0261F Q39756006-CFCADDC0-B1E5-4461-A957-CD6C0C744AB1

P2860

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

http://www.wikidata.org/entity/Q30474415

description

2011 nî lūn-bûn

@nan

2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

@ast

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

@en

type

label

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

@ast

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

@en

prefLabel

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

@ast

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

@en

P1433

Q30474415-5FC6E234-832E-4F42-B288-C92596496F20

P1476

Q30474415-1E96D96E-DF41-4514-BE15-E247308F69E4

P2093

Q30474415-EA52FC51-B3A3-42D7-93C5-C73735E843A8

P2860

Q30474415-02DFD5E7-1E4D-4F36-80FB-D6E99E9B24A6

Q30474415-04CA3F3C-CA92-4C4C-ADB9-560338A00614

Q30474415-051A0F50-FFCA-4FA7-B8E2-8C429C37FB18

Q30474415-05F570A5-6CBA-47AD-8810-BFB545805B26

Q30474415-099B5ED1-27BF-457A-B7EF-84E2A5785748

Q30474415-09B22A43-C321-4416-BF2B-ADF0E7E51283

Q30474415-0E9EA844-01EF-4FE0-8233-39C3FE839AD6

Q30474415-103B9A77-C759-4175-8296-0BDA121E0C35

Q30474415-116C1BB6-E601-4ADA-996B-DE90AA61FF0E

Q30474415-135DAD36-AB2D-43E1-A5EB-062CD8902EC7

P304

Q30474415-D1987C74-E31E-492F-A39D-FB8AA68AA384

P31

Q30474415-9E2BBBBB-3ED9-48EB-AC81-5F452CB93E33

P356

Q30474415-D6ACF0FB-C451-4284-A398-F03D831B9C58

P478

Q30474415-E7F7BF62-D52A-4706-9A7C-A4A4E83EA4D5

P577

Q30474415-1CCCADF2-1E57-4E5A-9218-425AB0D28E7A

P5875

Q30474415-30EE49CE-AA5A-432B-B282-5844040B3813

P698

Q30474415-657DF5B6-2599-4B14-B9FC-6F902AF26553

P932

Q30474415-4C33C01C-C907-4872-B3A2-BF3F796C2BC0

P356

FNMOL.2011.00016

P1433

Frontiers in molecular neuroscience

P1476

Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

@en

P2093

Richard Scott Jope

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning and characterization of a mammalian lithium-sensitive bisphosphate 3'-nucleotidase inhibited by inositol 1,4-bisphosphate

Animal models of depression: navigating through the clinical fog

Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor

A beta-arrestin 2 signaling complex mediates lithium action on behavior

An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior

Association of GSK3beta polymorphisms with brain structural changes in major depressive disorder

Disrupted in schizophrenia 1 regulates neuronal progenitor proliferation via modulation of GSK3beta/beta-catenin signaling

Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3

Role that phosphorylation of GSK3 plays in insulin and Wnt signalling defined by knockin analysis

Direct, activating interaction between glycogen synthase kinase-3beta and p53 after DNA damage

P304

16

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FNMOL.2011.00016

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2011-08-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51614266

http://www.w3.org/2001/XMLSchema#string

P698

21886606

http://www.w3.org/2001/XMLSchema#string

P932

3152743

http://www.w3.org/2001/XMLSchema#string